cbdMD Review – Good Products, and a Guarantee Worth Reading Twice

What cbdMD Is and Who It Is For

cbdMD is one of the larger and better-known US CBD brands, selling tinctures, gummies, softgels, topicals, sleep formulations, pet products and a delta-9 THC line. It is publicly traded, which matters more to this review than it usually would.

On product quality it is one of the strongest brands we have assessed — independent testing scores it highly, and the tinctures are genuinely good value per milligram.

On the company behind it there is a specific and material caveat, disclosed by cbdMD itself in its own audited filings, and it bears directly on the one feature most buyers rely on: the 60-day money-back guarantee.

The Testing, Which Is Strong

Start with what cbdMD does well, because it does this better than most.

Two details worth drawing out. Residual solvents on the panel is a meaningful inclusion — it addresses extraction chemistry that many brands never test for and few buyers think to ask about. And naming the laboratory is a small thing that separates verifiable testing from a marketing line, since it means someone can go and check.

For balance: Leafreport’s market-wide category reports graded the segments cbdMD competes in at B for pet products, B for topicals and C for edibles — those are category scores rather than cbdMD-specific ones, but they are a reminder that edibles as a class test less accurately than tinctures do.

Pricing, and Why It Is Better Than It Looks

Leafreport reports cbdMD across a range of $0.05 to $0.10 per mg, with mid-strength products around $0.08 against a competitor range of $0.08 to $0.17. Taken alone that looks mid-to-expensive. The tincture maths tells a better story.

A 1500mg tincture listed around $59.99 is roughly 4.0 cents per mg at full price, and with a subscription discount of about 30% near 2.8 cents — which makes it the second-cheapest CBD we have priced, behind only R&R and ahead of Extract Labs. That is a genuinely good number from a brand with independent verification behind it.

The catalogue-wide $0.05–$0.10 range is dragged upward by gummies and topicals, which cost more per milligram everywhere. If you want value from cbdMD, buy the tinctures. Subscriptions also carry free shipping with no minimum, and there are discounts reported up to 40% for military, nurses and frontline workers.

The Going Concern Disclosure

Because cbdMD is publicly traded, it files audited financials — and those filings contain something most CBD brands would never have to disclose.

It is worth being precise about what this is. “Going concern” is a formal accounting term, and a substantial-doubt disclosure means management and auditors have concluded there is real uncertainty about the company continuing to operate over the next twelve months absent improvement or new money. This is the company’s own statement about itself, not an outside allegation or an analyst’s opinion.

For context on the scale: $2.64 million in cash is a modest cushion for a business of this size. We reviewed another public company in this series with a debt-free balance sheet and $41.1 million in cash — that is the comparison that makes these numbers legible.

What That Means for the 60-Day Guarantee

Here is why the financial disclosure belongs in a product review rather than only in a stock analysis.

This is not us predicting anything. It is simply that a 60-day guarantee from a company with $2.64 million in cash and a going-concern disclosure is worth less than an identical guarantee from a company with a strong balance sheet — and a buyer choosing between brands on the strength of the returns policy should price that in.

The practical rule is straightforward and not especially dramatic: spend an amount you would be content to have spent if the refund never arrived. For a $60 tincture, that is a perfectly manageable risk and we would take it. For several hundred dollars of prepaid subscription, it is not.

Do Not Take the Prepay Subscription

cbdMD’s Subscribe & Save offers reported discounts of 25% to 35%, and the structure matters: you choose how often you want delivery, and whether to pay as you go or prepay and save up to 35%.

At around 25% off with free shipping and no minimum, pay-as-you-go still gets you the tincture near 3 cents per milligram, which remains excellent value. You are giving up a few percentage points to keep your money until the moment goods ship. That is a good trade.

The Case Against Overreacting

Having spent three sections on the financial risk, fairness requires the other side, and it is substantive.

• A going concern disclosure is not a prediction of failure. It is a formal flag that gets triggered by specific accounting tests. Companies carry one for years and recover, and the disclosure itself often prompts the corrective action.
• The trend is going the right way. Quarterly net sales rose to $5.6 million from $4.7 million a year earlier — meaningful growth — and the net loss narrowed 41% to roughly $877,000, with an operating loss of about $800,800 for the quarter. Those are improving numbers, not deteriorating ones.
• The losses are modest in absolute terms. A company losing under $1 million a quarter while growing sales is much closer to break-even than the phrase “going concern” might suggest to a casual reader.
• You are buying a physical product that ships immediately. Unlike a service subscription or a warranty on a durable good, a tincture that arrives is yours regardless of what happens afterwards. The exposure is genuinely limited to refunds and undelivered prepaid orders.

The honest summary is that this is a risk to manage, not a reason to avoid the brand. Buy a normal amount, do not prepay, and the disclosure barely touches you.

Litigation and Regulatory Position

Two matters, both several years old, and neither a finding of liability:

• A class action concerning data breaches reported to have occurred between March and May 2020.
• A California class action filed in December 2019 alleging violations of state unfair competition, false advertising and consumer remedies law along with warranty claims. A court stayed that action pending FDA rulemaking or Congressional legislation on CBD definitions, marketing and labelling.

That stay is worth a moment, because it says something about the whole industry. A court paused a false-advertising case because there is no settled federal standard to judge CBD labelling against — and years later, that clarity still has not fully arrived. It is a neat illustration of why independent testing matters so much in this category: there is no regulator doing it for you.

Side Effects, Interactions and Who Should Not Use It

Speak to a clinician first if you are:

• Pregnant or breastfeeding.
• Taking prescription medication. CBD can interact with drugs metabolised via liver cytochrome P450 enzymes, including some blood thinners and anti-epileptics.
• Living with liver disease or raised liver enzymes.
• Subject to drug testing — broad spectrum is formulated THC-free and lower risk, but full spectrum contains trace THC and the delta-9 line certainly will trigger a positive.
• Giving anything to a child, without paediatric advice.

Commonly reported CBD side effects include drowsiness, diarrhoea, dry mouth, reduced appetite and changes in liver enzymes. None of these products is FDA-approved to diagnose, treat, cure or prevent any disease, and no outcome is guaranteed. The delta-9 THC line falls within the federal hemp redefinition taking effect 12 November 2026, which caps hemp products at 0.4mg of THC per container; the core CBD range is far less exposed.

How It Compares

An important caveat on that last row. cbdMD looks worse than its private competitors on financial position partly because it discloses. Extract Labs and FOCL are private companies with no obligation to publish anything — they may be in robust health or they may not, and neither we nor you can tell. Being able to see a risk is not the same as being the only company that has one, and it would be perverse to penalise transparency too heavily.

On the metrics we can compare directly, cbdMD does well: the highest independent score of the three and the lowest cost per milligram.

Pros and Cons

Who Should Buy, and Who Should Look Elsewhere

Buy here if you want well-tested CBD at a genuinely competitive price and you are buying a normal quantity. A 1500mg tincture at around 2.8 cents per milligram subscribed, from a brand scoring 4.5 out of 5 with an independent assayer and testing through a named lab across a full contaminant panel, is a strong offer. Buy the tinctures specifically — that is where the value is.

Do not prepay a subscription, and do not buy a large quantity on the strength of the guarantee. Those are the two ways the financial disclosure could actually cost you something, and both are easy to avoid.

Look elsewhere if the returns policy is the reason you were choosing this brand. Extract Labs offers the same 60-day window from a company that has not flagged doubt about its own continuation — and does not require you to post anything back.

And not for weight loss. There is no good evidence CBD produces it, cannabinoids are more often associated with increased appetite, and nothing here has been studied alongside GLP-1 medications.

Limitations of This Review

We have not bought, used or independently tested any cbdMD product. The testing results here are Leafreport’s work, not ours, and reflect specific products and batches at the time of assay rather than a guarantee about your bottle.

Specific gaps: financial figures are as reported by third-party coverage of cbdMD’s filings rather than read from the filings themselves, and a single quarter is not a trend. We did not establish the current status of the NYSE American compliance requirement or whether it has since been satisfied. We could not confirm the exact current subscription discount, with reported figures spanning 25% to 35%, or the current tincture price — verify at checkout. We did not read the full 60-day guarantee terms, including whether product must be returned or who pays postage. Litigation is described from secondary reporting; neither matter represents a finding of liability and we did not establish current status. No FDA warning letter was located, but absence of a search finding is not proof of absence.

Our reasoning about the guarantee is an inference from a disclosed financial position, not a prediction about the company. Nothing here is financial advice or medical advice.

Frequently Asked Questions

Verdict

On product, cbdMD is near the top of this category. A Leafreport score of 4.5 out of 5, testing through a named laboratory across a panel that includes residual solvents and mycotoxins rather than potency alone, a tested product inside the variance limit with no microbiological impurities, and a 1500mg tincture at roughly 2.8 cents per milligram subscribed — cheaper than Extract Labs and a third of FOCL. If this were only a product review it would score well above this.

The deduction is not about the CBD. cbdMD is publicly traded and has disclosed substantial doubt about its ability to continue as a going concern without improved profitability or new funding, with $2.64 million in cash and listing compliance requirements outstanding. That matters here specifically because the brand’s headline benefit is a 60-day money-back guarantee — and a guarantee is only ever as good as the company standing behind it.

We want to be fair about the size of this. It is not a prediction of failure — sales grew to $5.6 million from $4.7 million, losses narrowed 41% to under $900,000, and companies carry these disclosures and recover routinely. It is also worth noting that cbdMD only looks riskier than its private competitors because it is obliged to tell you. Extract Labs and FOCL disclose nothing; that is not the same as having nothing to disclose.

So the conclusion is a managed one rather than a warning off. Buy the tinctures, take the pay-as-you-go subscription instead of prepaying, and spend an amount you would be relaxed about if a refund never came. Do that and you get some of the best-verified CBD available at close to the lowest price we have found — with the one real risk engineered out of the transaction.